CY1121952T1 - Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα - Google Patents

Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα

Info

Publication number
CY1121952T1
CY1121952T1 CY20171101247T CY171101247T CY1121952T1 CY 1121952 T1 CY1121952 T1 CY 1121952T1 CY 20171101247 T CY20171101247 T CY 20171101247T CY 171101247 T CY171101247 T CY 171101247T CY 1121952 T1 CY1121952 T1 CY 1121952T1
Authority
CY
Cyprus
Prior art keywords
bioavailability
crystallization method
phosphono
imidazol
vitro
Prior art date
Application number
CY20171101247T
Other languages
English (en)
Inventor
Mazen Hanna
Ning SHAN
Miranda Cheney
David Weyna
Raymond K. Houck
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1121952T1 publication Critical patent/CY1121952T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Παρασκευή, in-vitro και in vivo χαρακτηρισμός νέων μορφών (1-υδροξυ-2-ιμιδαζολ-1-υλ-1-φωσφονο-αιθυλ) φωσφονικού οξέος, κατάλληλων για φαρμακευτικές συνθέσεις σε συστήματα αποδέσμευσης φαρμάκων για ανθρώπους.
CY20171101247T 2009-07-31 2017-11-28 Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα CY1121952T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23022209P 2009-07-31 2009-07-31
US28803609P 2009-12-18 2009-12-18
US30211010P 2010-02-06 2010-02-06
US31287910P 2010-03-11 2010-03-11
US31850310P 2010-03-29 2010-03-29
US35954410P 2010-06-29 2010-06-29
PCT/US2010/043892 WO2011014766A2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability

Publications (1)

Publication Number Publication Date
CY1121952T1 true CY1121952T1 (el) 2020-07-31

Family

ID=43527595

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101247T CY1121952T1 (el) 2009-07-31 2017-11-28 Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα

Country Status (20)

Country Link
US (5) US8399023B2 (el)
EP (2) EP2459176B1 (el)
JP (1) JP5852569B2 (el)
KR (1) KR101813728B1 (el)
CN (1) CN102573809B (el)
AU (2) AU2010278860B2 (el)
CA (1) CA2769633C (el)
CY (1) CY1121952T1 (el)
DK (1) DK2459176T3 (el)
ES (1) ES2650665T3 (el)
HR (1) HRP20171755T1 (el)
HU (1) HUE034784T2 (el)
IL (1) IL217828B (el)
IN (1) IN2012DN01216A (el)
LT (1) LT2459176T (el)
NO (1) NO2459176T3 (el)
PL (1) PL2459176T3 (el)
PT (1) PT2459176T (el)
SI (1) SI2459176T1 (el)
WO (1) WO2011014766A2 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2458996B1 (en) * 2009-07-31 2016-09-07 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
SI2459176T1 (en) 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
US20160016982A1 (en) * 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
LT2531200T (lt) * 2010-02-06 2017-09-25 Grünenthal GmbH Kristalizacijos būdas ir bioprieinamumas
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US20140349974A1 (en) * 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
CN108434154A (zh) * 2013-10-25 2018-08-24 安泰赛普生物风投二代有限责任公司 用于治疗疾病的唑来膦酸或相关化合物的经口施用组合物
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US9079927B1 (en) 2014-05-27 2015-07-14 Antecip Bioventures Ii Llc Substituted imidazolium compounds for treating disease
US9688765B2 (en) 2014-06-11 2017-06-27 Antecip Bioventures Ii Llc Methods using RANK/RANKL antagonist antibodies for treating pain
CA2997378A1 (en) * 2015-09-18 2017-03-23 Grunenthal Gmbh Crystallization method and bioavailability
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN112778365A (zh) * 2020-12-30 2021-05-11 华南理工大学 一种唑来膦酸钙配合物及其制备方法

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959361A (en) 1970-03-20 1976-05-25 Joh. A. Benckiser Gmbh Process of producing amino methylene phosphonic acids
US3961934A (en) 1974-12-19 1976-06-08 Monsanto Company Method for increasing the sucrose content of growing plants
DE10199052I1 (de) * 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
IE912115A1 (en) * 1990-06-25 1992-01-01 Takeda Chemical Industries Ltd Bisphosphonic acid derivatives, their production and use
DK0573604T3 (da) 1991-02-26 1995-05-29 Procter & Gamble Pharma Fremgangsmåde til behandling af osteoporosis
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
KR970705400A (ko) 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
US6541454B1 (en) * 1995-04-04 2003-04-01 Yissum Research Development Company Of The Hebrew University Jerusalem Phosphonates, biphosphonates and pharmaceutical compositions containing them
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
NZ503946A (en) 1997-06-11 2003-02-28 Procter & Gamble Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
ES2301477T3 (es) 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
SE9901272D0 (sv) 1999-04-09 1999-04-09 Astra Ab New improved formulation
CA2370769A1 (en) 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates
WO2000071104A2 (en) * 1999-05-21 2000-11-30 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
CN1446093A (zh) * 2000-04-07 2003-10-01 得克萨斯系统大学董事会 两性离子型磷脂和双膦酸酯的独特组合物及其作为降低肠胃毒性的双膦酸酯释放系统的应用
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
DK1284754T3 (da) * 2000-05-05 2006-05-01 Hoffmann La Roche Gel-lignende farmaceutisk præparat som omfatter biphosphonsyrer eller salte deraf til subkutan administration
KR100864743B1 (ko) * 2000-06-20 2008-10-22 노파르티스 아게 비스포스포네이트의 투여 방법
RU2288722C2 (ru) 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
MXPA03000520A (es) * 2000-07-17 2003-10-06 Yamanouchi Pharma Co Ltd Composicion farmaceutica mejorada en absorbabilidad peroral..
SK9862003A3 (en) * 2001-02-06 2004-02-03 Royal Alexandra Hosp Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
CN1492763B (zh) * 2001-03-01 2012-05-23 艾米斯菲尔技术有限公司 用于递送二膦酸盐的组合物
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
EE200300530A (et) 2001-04-30 2004-04-15 Novologix Gmbh EF-Tu proteiiniga seostuvate ainete kasutamine antibakteriaalse vahendi valmistamiseks, sel viisil saadud antibakteerikum ning meetod uute bakterivastaste toimeainete identifitseerimiseks
JP2004528365A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法
JP2004528340A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト ビスホスホネートの医薬的使用
WO2002092616A1 (en) * 2001-05-11 2002-11-21 Orasense, Ltd. Antisense permeation enhancers
CA2454200A1 (en) 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
PT1443942E (pt) * 2001-10-19 2008-04-07 Novartis Ag Composição farmacêutica para utilização no tratamento de patologias malignas incluindo em combinação um bisfosfonato, um inibidor de cox-2 e um taxol
WO2003051373A1 (en) 2001-12-13 2003-06-26 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
ITMI20020908A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
ATE376444T1 (de) * 2002-05-10 2007-11-15 Hoffmann La Roche Ibandronsäure zur behandlung und vorbeugung von osteoporose
WO2003097655A1 (en) * 2002-05-17 2003-11-27 Teva Pharmaceutical Industries Ltd. Use of certain diluents for making bisphosphonic acids
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
GB0220885D0 (en) 2002-09-09 2002-10-16 Novartis Ag Organic compounds
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
CN1705485A (zh) 2002-10-15 2005-12-07 诺瓦提斯公司 施用双膦酸类化合物的方法
BR0309691A (pt) 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
US20060173009A1 (en) * 2003-01-07 2006-08-03 Hiroyuki Kanoh Agent inducing increase in bone mass
US20040230076A1 (en) * 2003-02-27 2004-11-18 Revital Lifshitz-Liron Process for purification of zoledronic acid
ATE550022T1 (de) 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmazeutische mischkristalle von celecoxib- nicotinamid
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
GB0310919D0 (en) 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20080058297A1 (en) 2003-05-29 2008-03-06 Synta Pharmaceuticals Corp. Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss
EP1567533B1 (en) * 2003-07-03 2009-03-11 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
WO2005044831A2 (en) 2003-08-21 2005-05-19 Sun Pharmaceutical Industries Limited A process for preparation of bisphosphonic acid compounds
MY141763A (en) 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
WO2005048979A2 (en) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US20050244485A1 (en) 2003-10-14 2005-11-03 Tsung-Min Hsu Transdermal administration of hydrophilic drugs using a basic permeation enhancer composition
AR046773A1 (es) 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
WO2005063717A1 (en) 2003-12-26 2005-07-14 Natco Pharma Limited An improved process for the preparation of zoledronic acid
WO2005099676A2 (en) 2004-04-07 2005-10-27 Dermatrends, Inc. Transdermal delivery system for use with basic permeation enhancers
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
AU2011218625B2 (en) 2004-05-24 2014-03-20 Theramex HQ UK Limited Dosage forms of risedronate
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
CA2566798A1 (en) 2004-05-24 2005-12-08 The Procter & Gamble Company Enteric solid oral dosage form of bisphosphonate containing a chelating agent
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20050289182A1 (en) 2004-06-15 2005-12-29 Sand Hill Systems Inc. Document management system with enhanced intelligent document recognition capabilities
US20060069069A1 (en) * 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses
WO2006020009A1 (en) 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
EP1781258A1 (en) 2004-08-20 2007-05-09 Mepha AG Formulations of bisphosphonates
US20060068010A1 (en) 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060134190A1 (en) 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
US20060178439A1 (en) 2005-01-04 2006-08-10 Mohakhud Pradeep K Crystalline form of zoledronic acid
KR100815040B1 (ko) * 2005-01-31 2008-03-18 주식회사종근당 비스포스포네이트계 약물의 경구흡수 개선을 위한약제학적 조성물
US8257742B2 (en) * 2005-02-17 2012-09-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates for treating endometriosis
EP1865928A1 (en) * 2005-03-17 2007-12-19 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
AR057291A1 (es) 2005-05-06 2007-11-28 Medichem Sa Proceso para la preparacion de acidos bisfosfonicos geminales y las sales y/o hidratos farmaceuticamente aceptables de los mismos, una composicion farmaceutica que los contiene y el uso de esta en el tratamiento de la osteoporosis
US20070014319A1 (en) 2005-07-15 2007-01-18 Zetetic Institute Continuously Tunable External Cavity Diode Laser Sources With High Tuning And Switching Rates And Extended Tuning Ranges
AR054673A1 (es) 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20080255366A1 (en) * 2005-09-12 2008-10-16 Dr. Reddy's Laboratories Limited Crystalline Trihydrate of Zoledronic Acid
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
US20070088161A1 (en) * 2005-10-19 2007-04-19 Stockel Richard F Novel chelated bisphosphonates for use as pharmaceutical agents
WO2007069049A2 (en) 2005-12-16 2007-06-21 Wockhardt Ltd Processes for the preparation of pure zoledronic acid
WO2007083240A2 (en) * 2006-01-20 2007-07-26 Aurobindo Pharma Limited An improved process for the preparation of bisphosphonic acids
EP1988907A4 (en) * 2006-02-06 2010-04-14 Cypress Bioscience Inc COMPOSITIONS COMPRISING A BISPHOSPHONATE AND AN ANTIFOLATE
EP1987046A1 (en) * 2006-02-20 2008-11-05 Alembic Limited An improved process for the preparation of biphosphonic derivatives
US20090137808A1 (en) * 2006-03-21 2009-05-28 Albemarle Corporation Process for manufacturing bisphosphonic acids
EP2007397B1 (en) 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
WO2007124274A1 (en) * 2006-04-21 2007-11-01 The Uab Research Foundation Treating neoplasms
WO2007125521A2 (en) 2006-05-02 2007-11-08 Ranbaxy Laboratories Limited Polymorphic form of zoledronic acid and processes for their preparation
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
WO2008040763A1 (en) 2006-10-05 2008-04-10 Novartis Ag Pharmaceutical compositions comprising bisphosphonates
EP1923394A1 (en) 2006-11-16 2008-05-21 Sandoz A/S Reagent and use thereof for the production of bisphosphonates
JP2010510195A (ja) * 2006-11-17 2010-04-02 ベシンズ・ヘルスケアー ビスホスホネート化合物を含む液体薬剤組成物
EP1925621A1 (en) 2006-11-27 2008-05-28 Novartis AG Crystalline forms of zoledronic acid
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
KR100775440B1 (ko) * 2006-12-20 2007-11-12 동우신테크 주식회사 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
AU2008229604B2 (en) 2007-03-20 2013-05-30 Scf Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US20090023683A1 (en) * 2007-07-16 2009-01-22 Chandrasekhar Kocherlakota Complexes comprising zoledronic acid and cyclodextrins
WO2009018834A1 (en) 2007-08-06 2009-02-12 Pharmathen S.A. Pharmaceutical composition containing bisphosphonate and method for the preparation thereof
KR101165455B1 (ko) 2007-09-10 2012-07-12 한스바이오메드 주식회사 인산칼슘 마이크로스피어 약물전달체 및 이의 제조방법
US20090099390A1 (en) 2007-09-24 2009-04-16 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronic acid and processes for the preparation thereof
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
US20090082312A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched zoledronic acid
ITPA20070034A1 (it) 2007-10-30 2009-04-30 Tetrapharm S R L Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
US8737985B2 (en) * 2007-11-26 2014-05-27 Wavemarket, Inc. Methods and systems for zone creation and adaption
NZ584219A (en) 2007-11-30 2012-03-30 Novartis Ag C2-c5-alkyl-imidazole-bisphosphonates
EP2217260B1 (en) 2007-12-04 2016-11-09 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
CN102015705B (zh) 2008-02-26 2013-11-13 武田药品工业株式会社 稠合的杂环衍生物及其用途
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
CA2720418A1 (en) 2008-04-04 2009-10-08 Novartis Ag Pharmaceutical composition with bisphosphonate
JP2009302891A (ja) 2008-06-13 2009-12-24 Sony Corp 情報処理装置
JP2011529902A (ja) 2008-07-31 2011-12-15 味の素株式会社 リセドロネートまたはその塩の低投与量形態
US8008329B2 (en) * 2008-08-01 2011-08-30 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate
WO2010060619A1 (en) 2008-11-26 2010-06-03 Synthon B.V. Process for making zoledronic acid
US20100158905A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
TWI480286B (zh) 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2458996B1 (en) 2009-07-31 2016-09-07 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
SI2459176T1 (en) 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
LT2531200T (lt) 2010-02-06 2017-09-25 Grünenthal GmbH Kristalizacijos būdas ir bioprieinamumas
WO2011132826A1 (en) 2010-04-19 2011-10-27 Snu R&Db Foundation Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases
US8946199B2 (en) * 2010-04-26 2015-02-03 Ketan Desai Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN102070668B (zh) 2010-12-23 2013-07-24 蚌埠丰原医药科技发展有限公司 一种利用相转移催化剂制备唑来膦酸及其钠盐的方法
US8993057B2 (en) 2011-10-22 2015-03-31 Masoud Salavati-Niasari Method for preparing silica-dysprosium oxide core-shell nanoparticles
US20130303488A1 (en) 2012-05-14 2013-11-14 Herriot Tabuteau Compositions Comprising Zoledronic Acid or Related Compounds for Treatment of Complex Regional Pain Syndrome
US20140349974A1 (en) 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
CN103070668A (zh) 2013-01-02 2013-05-01 北京工业大学 心脏年龄检测仪及其检测方法
WO2015051327A1 (en) 2013-10-04 2015-04-09 The Regents Of The University Of California Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells
CA2997378A1 (en) 2015-09-18 2017-03-23 Grunenthal Gmbh Crystallization method and bioavailability
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Also Published As

Publication number Publication date
JP2013500995A (ja) 2013-01-10
KR101813728B1 (ko) 2017-12-29
EP2459176B1 (en) 2017-09-27
AU2016219654B2 (en) 2018-05-31
US10323052B2 (en) 2019-06-18
DK2459176T3 (en) 2017-12-04
EP2459176A2 (en) 2012-06-06
JP5852569B2 (ja) 2016-02-03
US20140057875A1 (en) 2014-02-27
EP3295935A3 (en) 2018-04-18
IL217828A0 (en) 2012-03-29
HUE034784T2 (en) 2018-02-28
IL217828B (en) 2019-09-26
CA2769633C (en) 2017-06-06
LT2459176T (lt) 2017-12-11
US9334296B2 (en) 2016-05-10
US20110028435A1 (en) 2011-02-03
HRP20171755T1 (hr) 2017-12-29
EP3295935B1 (en) 2020-07-22
KR20120047275A (ko) 2012-05-11
AU2010278860B2 (en) 2016-05-26
US20180333425A1 (en) 2018-11-22
CA2769633A1 (en) 2011-02-03
PL2459176T3 (pl) 2018-02-28
NO2459176T3 (el) 2018-02-24
CN102573809A (zh) 2012-07-11
PT2459176T (pt) 2017-12-11
US20170022226A1 (en) 2017-01-26
CN102573809B (zh) 2017-07-21
SI2459176T1 (en) 2018-01-31
US20140107076A1 (en) 2014-04-17
AU2010278860A1 (en) 2012-02-16
EP2459176A4 (en) 2013-01-30
ES2650665T3 (es) 2018-01-19
US8933057B2 (en) 2015-01-13
WO2011014766A2 (en) 2011-02-03
US8399023B2 (en) 2013-03-19
IN2012DN01216A (el) 2015-04-10
EP3295935A2 (en) 2018-03-21
WO2011014766A3 (en) 2011-04-07
AU2016219654A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
CY1121952T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
CY1122687T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
CY1122628T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
WO2013052647A3 (en) Formulations and uses of retinoic acid receptor selective agonists
WO2011157416A3 (de) Transdermale verabreichung von memantin
EP2321640A4 (en) FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
SG2014010680A (en) Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease
DK3479863T3 (da) Sammensætninger, fremgangsmåder og artikler indeholdende farmaceutisk nitrogenoxid og regulerede leveringssystemer deraf til patienter
PH12015502556A1 (en) Modified release formulation
BRPI0810025A2 (pt) Formulação farmacêutica oral de liberação imediata, método para preparar uma formulação farmacêutica multiparticulada, e, uso de ácido ursodesoxicólico
FR2915683B1 (fr) Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
CY1115322T1 (el) Εκχυλισμα τριγωνελλας για τη θεραπεια νοσων στον ανθρωπο και τα ζωα στις οποιες εμπλεκονται μαστιγομορφα παρασιτα
MX2013007959A (es) Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
WO2015017423A3 (en) Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
CY1111495T1 (el) Νεα παραγωγα του 3-φαινυλο-προπανοϊκου οξεος, ενεργοποιητες των υποδοχεων τυπου ppar, μεθοδος παρασκευης τους και χρηση αυτων σε κοσμητικες ή φαρμακευτικες συνθεσεις
DK2344166T3 (da) Farmaceutisk præparat til behandlingen af gastrointestinale irritationslidelser
TR201100151A2 (tr) İbandronate formülasyonu.
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин